Retatrutide: what it is, where it stands in the UK, and how to read its certificate.
A factual overview for laboratories and procurement teams. Sources are linked at the end. Nothing here is medical advice, and nothing here is a claim of therapeutic effect.
What retatrutide is
Retatrutide (development code LY3437943) is an investigational synthetic peptide developed by Eli Lilly. It is a single molecule engineered to act as an agonist at three receptors: glucose-dependent insulinotropic polypeptide (GIP), glucagon-like peptide-1 (GLP-1) and glucagon. It is studied in metabolic research and, as of the review date above, is not licensed as a medicine in any country.
Retatrutide belongs to the incretin-based class of peptides. Where earlier molecules in this class act at one receptor (GLP-1 alone) or two (GIP and GLP-1), retatrutide's design adds glucagon-receptor activity. Published research examines how the three pathways interact in controlled experimental models.
The triple-agonist mechanism
Receptor pharmacology is described here for research context only.
- GIP receptor — studied in insulinotropic and metabolic signalling models; helps researchers map the incretin axis beyond GLP-1 alone.
- GLP-1 receptor — the best-characterised incretin pathway in the literature; investigated in energy-balance and incretin-signalling research.
- Glucagon receptor — explored in hepatic glucose and energy-expenditure models; the component that distinguishes a triple agonist from dual-agonist molecules.
UK regulatory status
Retatrutide has not been authorised by the Medicines and Healthcare products Regulatory Agency (MHRA). It cannot be legally prescribed, supplied or advertised for human use in the UK outside authorised clinical trials. The MHRA has stated publicly that products promoted online as retatrutide for weight loss are unlicensed, that their contents and manufacturing standards are unknown, and that it is taking enforcement action against manufacturers and sellers.
Between October 2025 and May 2026 the MHRA reported a series of raids on illegal manufacturing and distribution sites in the East Midlands, seizing thousands of doses of unlicensed weight-loss products; across 2025 it reported 28.5 million doses of illegally traded medicines seized with an estimated value of £64.4 million. Reta Dynamic does not sell, advertise or supply any product for human use and does not make any claim about human effects.
The legal position for research supply
Retatrutide is not a controlled substance under the Misuse of Drugs Act 1971 or the Psychoactive Substances Act 2016. It is an unlicensed investigational compound, so the Human Medicines Regulations 2012 apply: it may not be sold, supplied or advertised for human use. Supply of research-grade material to laboratories and research organisations for in-vitro and approved research is a separate activity, and it is the only activity Reta Dynamic carries out.
That is why every Reta Dynamic order passes through trade verification — Companies House number, business type, document-based identity check and a signed research-use declaration — and why we do not sell to individuals or the public.
How to read a retatrutide COA
A certificate of analysis (COA) is only useful if you know what it should contain. A credible batch certificate for a research peptide answers two different questions with two different methods.
1. Purity — HPLC
High-performance liquid chromatography separates the sample into its components. The purity figure is the area of the main peak as a percentage of all detected peaks. Look for: the method and column stated, a chromatogram (not just a number), the batch/lot number on the certificate matching the label, and the testing date.
2. Identity — mass spectrometry
Mass spectrometry confirms that the measured molecular mass matches the expected mass of the target molecule. A high HPLC purity figure without identity confirmation only tells you the sample is mostly one thing — not that it is the right thing.
3. Who signed it
A manufacturer's own certificate is layer one. Independent re-testing by a third-party laboratory is layer two — this is what Reta Dynamic calls a dual-layer COA. Check the laboratory is named, its accreditation is stated and verifiable, and the batch code on the certificate matches the box, the invoice and the online record.
See the Reta Dynamic COA library →
Pen format vs vial
Most research peptides are supplied as lyophilised powder in a vial. Reta Dynamic supplies retatrutide in a sealed, dial-metered pen cartridge with 12 sterile single-use needles, batch-labelled and serial-matched to its certificate. The pen is not a medical device and the kit contains no use or dosing instructions; it is supplied for laboratory research use only.
Questions
What is retatrutide?
Retatrutide (development code LY3437943) is an investigational synthetic peptide developed by Eli Lilly. It is a single molecule designed to act at three receptors — GIP, GLP-1 and glucagon — and is being studied in metabolic research. It is not a licensed medicine anywhere in the world as of the date this page was reviewed.
Is retatrutide licensed or available in the UK?
No. Retatrutide has not been authorised by the MHRA. It cannot be legally supplied, prescribed or advertised for human use in the UK outside authorised clinical trials. Any product marketed for weight loss or human use is unlicensed and illegal to supply.
Is it legal to buy retatrutide in the UK for research?
Research-grade retatrutide is supplied to laboratories and research organisations for in-vitro and approved research only. It is not a controlled substance under the Misuse of Drugs Act 1971, but it is an unlicensed investigational compound: supplying it for human use, or advertising it for human use, is an offence under the Human Medicines Regulations 2012. Reta Dynamic supplies verified trade accounts only.
What does an HPLC purity figure mean?
High-performance liquid chromatography separates a sample into its components; the purity figure is the proportion of the main peak relative to all detected peaks (area %). It tells you how much of the sample is the target peptide versus related impurities. It does not by itself prove identity — that is what mass spectrometry is for.
Why does a COA need both HPLC and MS?
HPLC answers 'how pure is it?'; mass spectrometry answers 'is it the right molecule?' by confirming the measured molecular mass matches the expected mass of retatrutide. A certificate showing only one of the two leaves a question open.
What is a 'reta pen' and how does it differ from a vial?
A pen presents the research material in a sealed, dial-metered cartridge format rather than a lyophilised vial. Reta Dynamic supplies the pen format with batch-matched documentation and serialised verification for laboratory use only; it is not a medical device and is not supplied for human use.
How should research-grade retatrutide be stored?
Refrigerated at 2–8 °C, protected from light, not frozen, in the original sealed packaging until required. Follow your laboratory's SOPs for handling and disposal.
Sources
- MHRA — Medicines and Healthcare products Regulatory Agency: statements on unlicensed weight-loss medicines and enforcement activity, 2025–2026.
- The Pharmacist — Warning over unlicensed weight-loss drugs being sold on social media.
- Eli Lilly — retatrutide (LY3437943) clinical development programme disclosures and peer-reviewed publications on triple GIP/GLP-1/glucagon receptor agonism.
- UK legislation — Human Medicines Regulations 2012; Misuse of Drugs Act 1971.
For laboratory research use only. Not for human consumption. This page is provided for research context and procurement due-diligence only.